239 related articles for article (PubMed ID: 11791627)
1. The emerging role of atypical pathogens in community-acquired pneumonia.
Gleason PP
Pharmacotherapy; 2002 Jan; 22(1 Pt 2):2S-11S; discussion 30S-32S. PubMed ID: 11791627
[TBL] [Abstract][Full Text] [Related]
2. [The role of atypical pathogen: Mycoplasma pneumoniae and Chlamydia pneumoniae in the acute respiratory infection in childhood].
Ouchi K
Jpn J Antibiot; 2000 Jun; 53 Suppl B():13-21. PubMed ID: 12572086
[TBL] [Abstract][Full Text] [Related]
3. The atypical pneumonias: clinical diagnosis and importance.
Cunha BA
Clin Microbiol Infect; 2006 May; 12 Suppl 3():12-24. PubMed ID: 16669925
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Patel T; Pearl J; Williams J; Haverstock D; Church D
Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
[TBL] [Abstract][Full Text] [Related]
5. First report on prevalence and risk factors of severe atypical pneumonia in Vietnamese children aged 1-15 years.
Huong Ple T; Hien PT; Lan NT; Binh TQ; Tuan DM; Anh DD
BMC Public Health; 2014 Dec; 14():1304. PubMed ID: 25524126
[TBL] [Abstract][Full Text] [Related]
6. Community-acquired pneumonia: role of atypical organisms.
Cosentini R; Tarsia P; Blasi F; Roma E; Allegra L
Monaldi Arch Chest Dis; 2001 Dec; 56(6):527-34. PubMed ID: 11980285
[TBL] [Abstract][Full Text] [Related]
7. Atypical aetiology in patients hospitalised with community-acquired pneumonia is associated with age, gender and season; a data-analysis on four Dutch cohorts.
Raeven VM; Spoorenberg SM; Boersma WG; van de Garde EM; Cannegieter SC; Voorn GP; Bos WJ; van Steenbergen JE; ;
BMC Infect Dis; 2016 Jun; 16():299. PubMed ID: 27317257
[TBL] [Abstract][Full Text] [Related]
8. Importance of atypical pathogens of community-acquired pneumonia.
Plouffe JF
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S35-9. PubMed ID: 10984326
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of empiric macrolides versus fluoroquinolones in community-acquired pneumonia associated with atypical bacteria: A meta-analysis.
Basilim A; Wali H; Rabaan AA; Eljaaly K
Respir Med Res; 2022 Nov; 82():100931. PubMed ID: 35905552
[TBL] [Abstract][Full Text] [Related]
10. The incidence and etiology of community-acquired pneumonia in fever outpatients.
Bao Z; Yuan X; Wang L; Sun Y; Dong X
Exp Biol Med (Maywood); 2012 Nov; 237(11):1256-61. PubMed ID: 23239436
[TBL] [Abstract][Full Text] [Related]
11. Community-acquired pneumonia related to intracellular pathogens.
Cillóniz C; Torres A; Niederman M; van der Eerden M; Chalmers J; Welte T; Blasi F
Intensive Care Med; 2016 Sep; 42(9):1374-86. PubMed ID: 27276986
[TBL] [Abstract][Full Text] [Related]
12. Role of 'atypical pathogens' among adult hospitalized patients with community-acquired pneumonia.
Lui G; Ip M; Lee N; Rainer TH; Man SY; Cockram CS; Antonio GE; Ng MH; Chan MH; Chau SS; Mak P; Chan PK; Ahuja AT; Sung JJ; Hui DS
Respirology; 2009 Nov; 14(8):1098-105. PubMed ID: 19818051
[TBL] [Abstract][Full Text] [Related]
13. Etiology and antimicrobial resistance of community-acquired pneumonia in adult patients in China.
Tao LL; Hu BJ; He LX; Wei L; Xie HM; Wang BQ; Li HY; Chen XH; Zhou CM; Deng WW
Chin Med J (Engl); 2012 Sep; 125(17):2967-72. PubMed ID: 22932165
[TBL] [Abstract][Full Text] [Related]
14. Annual and seasonal patterns in etiologies of pediatric community-acquired pneumonia due to respiratory viruses and Mycoplasma pneumoniae requiring hospitalization in South Korea.
Lee E; Kim CH; Lee YJ; Kim HB; Kim BS; Kim HY; Kim Y; Kim S; Park C; Seo JH; Sol IS; Sung M; Song MS; Song DJ; Ahn YM; Oh HL; Yu J; Jung S; Lee KS; Lee JS; Jang GC; Jang YY; Chung EH; Chung HL; Choi SM; Choi YJ; Han MY; Shim JY; Kim JT; Kim CK; Yang HJ;
BMC Infect Dis; 2020 Feb; 20(1):132. PubMed ID: 32050912
[TBL] [Abstract][Full Text] [Related]
15. Chlamydia pneumoniae and Mycoplasma pneumoniae.
Blasi F; Tarsia P; Aliberti S; Cosentini R; Allegra L
Semin Respir Crit Care Med; 2005 Dec; 26(6):617-24. PubMed ID: 16388430
[TBL] [Abstract][Full Text] [Related]
16. Implications for macrolide treatment in community-acquired pneumonia. Hopkins CAP Team.
Mundy LM; Oldach D; Auwaerter PG; Gaydos CA; Moore RD; Bartlett JG; Quinn TC
Chest; 1998 May; 113(5):1201-6. PubMed ID: 9596295
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial therapy in community-acquired pneumonia among emergency patients in a university hospital in Japan.
Kawai S; Ochi M; Nakagawa T; Goto H
J Infect Chemother; 2004 Dec; 10(6):352-8. PubMed ID: 15614461
[TBL] [Abstract][Full Text] [Related]
18. [Epidemiology and Aetiology of Community-acquired Pneumonia (CAP)].
Pletz MW; Rohde G; Schütte H; Bals R; von Baum H; Welte T;
Dtsch Med Wochenschr; 2011 Apr; 136(15):775-80. PubMed ID: 21469047
[TBL] [Abstract][Full Text] [Related]
19. Acute Chlamydia pneumoniae and Mycoplasma pneumoniae infections in community-acquired pneumonia and exacerbations of COPD or asthma: therapeutic considerations.
Meloni F; Paschetto E; Mangiarotti P; Crepaldi M; Morosini M; Bulgheroni A; Fietta A
J Chemother; 2004 Feb; 16(1):70-6. PubMed ID: 15078002
[TBL] [Abstract][Full Text] [Related]
20. 13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents.
Roig J; Casal J; Gispert P; Gea E
Med Mal Infect; 2006; 36(11-12):680-9. PubMed ID: 17095177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
